IRADIMED (IRMD) Q2 FY26 earnings call

IRadimed delivered Q2 FY26 results in line with guidance, driven by the successful initial production ramp and strong customer acceptance of its new 3870 MR IV pump system. The company is focused on scaling production and improving manufacturing efficiencies in the second half of the year, anticipating a return to historical gross margins and strong growth rates. Management reaffirmed its full-year revenue and EPS guidance, projecting a $100 million revenue run rate by Q4 FY26.